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Guidance by physicians and pharmacists
during antidepressant therapy: patients’
needs and suggestions for improvement
Mariёtte Nederlof1,2, Daniёlle C. Cath3,4, Lennart J. Stoker1, Toine C. G. Egberts1,5 and Eibert R. Heerdink1,5,6*
Abstract
Background: Guidance of patients treated with antidepressants is paramount for successful therapy. The aim was
to assess patients’ needs and suggestions for improvement of guidance by physicians and pharmacists during
second generation antidepressant (SGA) therapy.
Methods: Five focus group discussions were held with a total of 34 patients using an SGA. The discussions were
conducted flexibly and responsively using a semi-structured topic list. All focus group discussions were video-
recorded and transcripts were analyzed using ATLAS.ti for coding, thematic and open analysis.
Results: Participants stated they were in need of better guidance. They suggested improving content of information
during decisional moments, patient-health care professional communication and communication between health care
professionals, and finally, organization of guidance. Barriers to achieving improved guidance were cited.
Conclusions: Content, communication and organization of guidance are pivotal for achieving optimal guidance.
Participants mentioned their current experienced guidance had limitations and brought up solutions for improvement.
A next step would be to discuss the suggested solutions with health care professionals to assess their views and to
discuss the possibility for implementation. After implementation, future studies could be aimed at determination of its
impact on patients’ treatment efficacy, quality of life, treatment satisfaction and healthcare costs.
Keywords: Qualitative research, Focus groups, Antidepressiva agents, Second-generation, Counseling, Patient
satisfaction, Professional role
Background
Antidepressant prescribing has increased significantly
over the last decades [1–3]. There are concerns about
over- as well as underdiagnosing patients and about
under- and overprescribing of antidepressants [4].
Health care professionals focus on a correct diagnosis in
patients with a major depressive or anxiety disorder,
choosing a suitable treatment strategy and guiding pa-
tients. Patients need monitoring and guidance at deci-
sional moments regarding treatment (Fig. 1). Shared
decision making, incorporating patients’ needs is recom-
mended [5, 6] and demands that both patient and health
care professional are involved, share information, reach
consensus about preferred treatment and implementa-
tion of treatment [7].
The effectiveness of treatment with antidepressants is
influenced by selecting optimal medication, guidance of
health care professionals and adherence of the patient to
treatment [8]. Between 40% and 70% of patients with a
major depressive or anxiety disorder fail to respond to
second generation antidepressants (SGA) and up to 90%
experience side effects [9–11]. Patients are facing mul-
tiple decisions before and during treatment that can in-
fluence adherence [12]. Approximately one in four
patients receiving a first-time prescription for an anti-
depressant either do not fill the prescription at all (4%)
or do not persist in use for longer than two weeks (24%)
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[12]. In addition, more than half of patients discontinue
within six months [13, 14].
Half of the patients who do not initiate SGA
treatment do so due to fear of side effects [15].
The decision to discontinue medication early can
be a result of limited guidance by health care pro-
fessionals during treatment, lack of knowledge and
use, a negative attitude towards SGA use and the
disease itself [15]. Patients who discontinue treat-
ment early, perceive counselling by general practi-
tioner and pharmacist as limited, both during
initiation and execution of treatment [15]. Lack of
guidance may also lead to unnecessary long dur-
ation of treatment.
In order to provide optimal guidance, the experiences
and views of patients should be known and taken into
account. Therefore, the objective of this study is to as-
sess patients’ needs and suggestions for improvement of
guidance by physicians and pharmacists during SGA
therapy.
Methods
The Institutional Review Board of the Division of Phar-
macoepidemiology and Clinical Pharmacology of Ut-
recht University and the Research Committee of
Altrecht Mental Healthcare reviewed and approved the
study protocol. All participants provided written in-
formed consent.
A qualitative approach was used to assess patients’
perspectives. Focus group discussions were held to as-
sess experiences with regard to guidance during SGA
therapy in-depth and to include the interaction with
other participants.
To recruit patients, approximately 2500 bro-
chures were dispensed in 40 community pharma-
cies from the Utrecht Pharmacy Practice network
for Education and Research (UPPER) [16]. To in-
clude a diverse patient population, patients were
also recruited at Altrecht Academic Anxiety
Centre, Utrecht (a specialized mental health insti-
tution on secondary and tertiary treatment of anx-
iety disordered patients). Patients aged ≥18 years
with a prescription for a second-generation anti-
depressant (Appendix) in the last twelve months
were eligible. The participants did not know the
researchers who conducted the focus groups before
inclusion.
Focus group discussions were held in a private
room for approximately two hours each, with six to
eight participants per group. One female re-
searcher (MN, PharmD), working additionally as
pharmacist, conducted all focus group discussions
using a semi-structured topic list, with a female
psychologist as research assistant (NF) and a male
second researcher as observer (EH, PhD). To gain
experience, the primary author participated in a
qualitative research training course. Thereafter, a
pilot focus group was held to practice and improve
the focus group setting. The objective of the study
was explained to participants before start of the
focus groups.
Group discussions were conducted flexibly and re-
sponsively, to enable participants’ narratives to
Fig. 1 Decisional moments before and during antidepressant use
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develop. Participants were asked to write down two
positive and two negative aspects of the guidance
during antidepressant therapy. These notes served
as basis for a brainstorm on recommendations for
improvement of guidance by physicians and phar-
macists. Participants were asked how they were
guided during antidepressant therapy and about
their opinion of received guidance using open-ended
questions. Thereafter, it was discussed how guidance
could be improved. Needs and suggestions for improve-
ment of participants were summarized and presented to
cross check their perspective. The number of focus group
discussions was judged sufficient if data saturation was
reached, discussed by the researchers after every focus
group (MN and EH).
All focus group discussions were video-recorded and
written down in their original language ad verbatim,
to preserve the participants’ original meanings. Tran-
scripts were imported and analyzed using ATLAS.ti
(Version 7.5; Scientific Software Development GmbH,
Berlin, Germany). Data were analyzed using an induct-
ive data-driven process known as the grounded theory
[17], a method of using empirical data without precon-
ceived theories. The first level of data analysis con-
sisted of a thematic analysis and the second of an
open analysis of all transcripts by the first author
(MN). A second author (EH) reviewed this analysis.
Identified codes were arranged into meaningful
themes and adjusted in a cyclic process with close in-
volvement of the second investigator (EH). Although
the data have not been discussed with the participants,
they can be in future after translation in their original
language.
Results
Five focus group discussions included a total of 34
patients using SGAs (Table 1). During focus group
discussions, multiple needs, barriers and sugges-
tions for improvement of guidance were mentioned.
At analysis, themes emerged; content of guidance,
communication aspects and organization of guid-
ance. Communication aspects were divided into
communication between patient and health care
professional and communication between health
care professionals.
Content of guidance
Participants wanted guidance not only to focus on
medication, but also on cause of symptoms and
non-pharmacological therapy. Some felt that gen-
eral practitioners prescribed an SGA too rapidly.
Information on what medication participants were
given, why this medication was chosen, discussing
alternative treatment options, mechanism of action,
assessment of harm-benefit balance and involving
the patient in the decision-making process was
needed.
Woman, 36 years: “They only assess how to solve the
symptoms of the depression, but not the cause.”





















Current user 31 91
Past user 3 9
Initial prescriber
Psychiatrist 21 62




Anxiety and depression 12 35
Other 2 6
Duration of SGA usage
0–6 months 3 9
6 months – 1 year 4 12
1–5 years 11 32
5–10 years 7 21
> 10 years 9 26
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Male, 39 years: “Another thing I worry about, is that
there are so many different antidepressants and they
never told me why I get this one drug.”
Incorporating a waiting time before initiation of
the SGA was suggested to consider the decision to
initiate treatment. A protocol for physicians could
help to select the most accurate medication and to
discuss information needed by patients. Participants
noticed that it differed per physician what medication
you receive; to the participants it seemed random.
To help choose the right medication, patient ques-
tions could be included, for example to assess which
symptoms are most prevalent for that specific pa-
tient. Monitoring of possible side effects or labora-
tory values was recommended and made participants
feel more supported.
Woman, 26 years: “Maybe a kind of protocol about
how guidance should be. I have the feeling that it
differs a lot between different physicians and that you
have to be lucky.”
Information needed to be provided on expected
effects, side effects, difficulty of discontinuing
treatment and potential worsening of symptoms
during start of treatment. Some patients had
doubts if they would have started treatment if they
had been informed on all side effects; others felt
incapable of making the choice to initiate treat-
ment due to the severity of their symptoms. Patient
leaflets were not always handed to patients in psy-
chiatric institutions.
Male, 63 years: “They put something in your mouth
in a psychiatric institution, but you have no idea
what it is.”
Woman, 26 years: “The physician could also
mention that if you experience these side effects,
you have to contact him. The side effects are of
course listed in the patient information leaflet, but
I think it is important that the physician mentions
them.”
Subjects that a physician should discuss during
treatment were worries, side effects, complaints, the
patients’ wellbeing, considering early discontinuation,
utilization of and experience with medication, the pa-
tient’s social network and suicidality. If needed, physi-
cians should discuss the possibility of switching
medication. The efficacy of the medication, com-
plaints, side effects and patients’ worries should be
discussed by the pharmacist too.
Woman, 45 years: “I would like to be monitored for
the side effects that I experience. How bothersome are
the side effects for me? What is the effect on my body?
Is there a safer medication or should the dosage be
adjusted?”
For patients, it would be helpful to have a guideline
to self-evaluate efficacy, dose and side effects of medi-
cation. It was difficult to evaluate efficacy as mood
can vary or to determine if a side effect was related
to the antidepressant. An evaluation form for patients
was proposed to assess all side effects, including sex-
ual side effects. This could help less assertive patients
to formulate questions preceding consultation. The
physician could then provide feedback on patients’
questions.
Woman, 34 years: “It can be a standard question
to fill in a form before your six-month-control. You
can write down how you feel and what your worries
are.”
Woman, 52 years: “I would like to fill out such a form
at initiation, after four weeks and so on to discuss side
effects. Are my side effects due to the medication or
due to something else?”
In case of long-term treatment, the physician
should assess and advice if it is necessary to con-
tinue, discontinue or adjust the dosage of medication.
Guidance during long-term use, dose adjustment and
after cessation should be available and based on
practical tips for dose reduction and by discussing
the patient’s wellbeing and experiences. The pro-
posed protocol could include the requirement to in-
form patients about treatment discontinuation and
methods to do so. Consultation after tapering was
recommended.
Woman, 67 years: “You receive the medication and
are thrown in the deep end. Do I take it for a year or
ten years or endless? You don’t know, but I do not
dare to cease treatment.”
Communication aspects
Communication between patient and health care
professional
Participants mentioned the need to be taken seriously
most often. Participants felt that not all psychiatrists
were empathic enough, especially in case of side effects
or during initiation or tapering off medication. Direct
contact, accuracy, respect and an attitude of thinking
along with the patient were essential.
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Woman, 29 years: “I was very depressed but my
psychiatrist was not empathic during initiation of
medication. At a moment I was unable to carry
on with the increase in dosage, because I had
such severe side effects. He mentioned: “You are
26 years old, behave like an adult.” In the end
that approach worked, but I thought it was
harsh.”
The autonomy of patients should be respected.
Shared decision making about dosage or choice of
antidepressant was experienced positively, while
other participants stressed the importance of being
able to make their own choices, based on good
advice.
Male, 48 years: “Yes, I am the boss beyond any doubt.
My internist is my manager.”
Mutual trust between physician and patient was
cited as being important for medication initiation and
believe in efficacy of treatment. Participants did not
completely trust their physician if they could not re-
call conversations, medication dosages, gave opposing
advice, made mistakes in prescriptions or were cha-
otic. Some participants liked the ability to choose for
a female or male physician.
Woman, 52 years: “I can send an email to my
psychiatrist if I think the dosage needs to be
adjusted and why. Then I can receive the
medication because he trusts me, he knows that I
know my body; I know when things go wrong, in the
direction of a depression. And I think that’s
fantastic.”
Hierarchy was noticeable for some participants and
made it difficult for them to discuss questions.
Equality was needed in verbal and non-verbal
communication.
Male, 63 years: “I did not get to see a psychiatrist,
only on the background the psychiatrist decided
what to do, evaluated how I acted and which
medication to choose. It confused me. In another
hospital communication was better and reports were
made every two weeks of my wellbeing.”
Communication between health care professionals
Communication between health care professionals
was seen as insufficient when advice was conflict-
ing or transfer of information was missing on the
patients’ medical history. Some participants felt
that communication between health care special-
ists in psychiatric institutions was better orga-
nized. It was sometimes unclear for participants
which health care professional to contact for
guidance.
Male, 61 years: “What I consider to be negative
is that psychiatrists establish different diagnoses.
For years I have taken a blue pill because I had
attention deficit hyperactivity disorder (ADHD).
Until the next psychiatrist said “That man does
not have ADHD” and I had to quit immediately.”
Male, 49 years: “I was often referred by the general
practitioner to the psychiatrist and the other way
around. But in between I was left to my fate and I
still am.”
Participants preferred to have a single health care pro-
fessional responsible, to keep track of treatment pro-
cesses. That health care professional should assess if
treatment is still adequate with respect to dosage, dur-
ation of use and the patients’ wellbeing. However, it was
difficult to decide who this responsible health care pro-
fessional should be.
Woman, 25 years: “I was 17 years old when I got
the prescription. My general practitioner was a bit
hesitant to prescribe because he thought I was
young, but after I called the psychiatrist I got the
prescription. I have also been to different clinics
and every time another person took over the
guidance as a consequence. What I have missed is
a kind of overall responsibility. Who is responsible
and keeps an eye on me?”
Organization of guidance
The preferred frequency of contact differed between
participants, but in general they felt it should be in-
tensified. Some participants mentioned that their
physician contacted them only once or a few times.
Others lost contact after long-term use of the
medication.
Male, 39 years: “Even when I was admitted on a
closed unit of a psychiatric hospital, I rarely got to see
a psychiatrist.”
Woman, 64 years: “My general practitioner prescribed
the medication, there was no follow up afterwards. I
can request repeat prescriptions. I think it is wrong
that he never asks about it or that there is no such
thing as a short conversation.”
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Participants explained that when you have a de-
pression or anxiety disorder you are inclined to re-
treat and avoid contact. Periodical consultations
during initiation of treatment were needed and after
every consultation it should be clear when the next
appointment is. Initiative for contact should come
from the physician, since not all patients are assert-
ive enough. Preferred frequency of contact was once
to every week during the first month and monthly
to every six months during maintenance therapy.
Further, duration of consults was perceived as
insufficient.
Woman, 47 years: “Only recognizing your feelings,
by proposing to set appointments every six weeks,
or to call at a fixed time once a month, whatever
you want. If a physician suggests that, it will
already be part of the solution, you then know it
is not going to be easy and someone is there for
me.”
Woman, 45 years: “The psychiatrist should
monitor, explain the mechanism of action and
side effects, should take care of a follow-up
appointment and is responsible to keep the general
practitioner updated about the use of that
medication.”
Some participants mentioned that they should pref-
erably be informed about SGA therapy with a relative,
friend, neighbor or somebody who is close to the pa-
tient present. Patients should not initiate an anti-
depressant without a relative or caregiver monitoring
them.
Woman, 36 years: “I honestly think a patient
should not be left alone during the first
day of medication initiation. It can even be
your mother or a friend who keeps an eye on
you.”
Woman, 29 years: “I totally agree. I had suicidal
thoughts during the first five days”.
It was sometimes difficult to reach a psychiatrist
when needed, for example when experiencing sui-
cidal thoughts or psychotic symptoms, side effects
at night, during weekends or during a medication
switch.
Woman, 59 years: “During the evenings and in the
weekends, there is no one and especially in those times
things are heading your way. I think that is a
disadvantage.”
In general, contact with pharmacists was limited.
It was appreciated if pharmacists explained the
choice of medication, asked about side effects,
checked for medication interactions, gave a medica-
tion review or supported with SGA tapering. Privacy
in pharmacies was perceived as inadequate; there-
fore, some participants preferred to phone about
questions. Participants thought it was frustrating
when medication was out of stock, when brands
changed frequently and costs for dispensing were
thought to be high.
Woman, 27 years: “I always speak to a pharmacy
assistant and I think it is not substantial enough. To
me pharmacists are primarily for the distribution of
medication.”
Some participants wondered why they could fill in re-
peat prescriptions, even through the Internet, for a long
time without a check. A participant mentioned that an
alert to pick up repeat medication would be appreciated
and suggested to contact a patient if the prescription
was not filled.
Woman, 26 years: “For repeat medication you have to
keep in mind that you should be in time. Once I was
very stressed because I was too late and you can get
withdrawal symptoms if you do not receive the
medication in time. It could possibly be improved with
announcements.”
A daily consultation hour by the physician or pharma-
cist was mentioned as a solution to increase contact, this
could even be by email or phone, and needed to be
provided within psychiatric institutions too. A stand-by
24-h service helpline for patients in need was men-
tioned, to be able to ask questions, receive information
and feel heard. When available, awareness for that possi-
bility should be created.
Woman, 28 years: “That people feel heard and do not
have to wait for a week. Especially during dose
increases or ceasing a drug, because that can cause
serious reactions such as suicidal thoughts and that
just can’t wait.”
Participants had mixed impressions on use of
eHealth solutions for guidance, such as a mobile ap-
plication. Some worried that contact would become
too frequent, it would be too busy for health care
professionals or had no smartphone. An anonymous
private forum with a chat function, monitored by a
psychiatrist was mentioned, although reading other
experiences could possibly make participants anxious.
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Contact with health care professionals by email was
appreciated.
Woman, 36 years: “I would prefer just face-to-face
contact.”
Woman, 45 years: “It would be a good aid to keep and
at least improve contact, to be able to communicate
experiences, to improve monitoring.”
Some participants were of opinion that only psychi-
atrists should prescribe antidepressants because of a
perceived limited knowledge of general practitioners
on side effects, alternative medication and medication
interactions. Knowledge of pharmacists was also
thought to be limited. Reasons not to have a psych-
iatrist as prescriber were related to a better relation-
ship with the general practitioner or because
participants did not want more consultations with the
psychiatrist.
Man, 63 years: “If I feel worse again, I would go to the
psychiatrist. I do not have trust that the general
practitioner is appropriately qualified.”
Male, 49 years: “You go with side effects to the
general practitioner, you mention them and then
you have to choose. What medication do you
want?”
Woman, 28 years: “Yes that is what you are being
asked, as if you are the expert!”
Discussion
Participants reported their current experienced guid-
ance had limitations and brought up solutions for
improvement and potential (already experienced) bar-
riers. Consistent with previous work, we found con-
tent to be important for satisfaction with a
consultation [18]. Counselling is not a single event,
but a process over time [19, 20]. Providing treatment
expectations and knowledge may improve adherence
and treatment success [21, 22]. Our study showed
that patients were in need of information throughout
treatment for decision making, at start of treatment,
during continuation and at end of treatment. Clear
advice during decisional moments was essential, in-
cluding what to expect regarding effects and side
effects.
Shared decision making, involving patients in treat-
ment decisions and incorporating patients’ preferences,
was of major importance, which is in agreement with
other (qualitative) studies [21, 23–25].
Previously, patients have emphasized the import-
ance of communication and behavior of health care
professionals, rather than the amount of time the
practitioner provided [6]. Percival et al. reported
that patients felt like they were given sufficient time
when practitioners focused attentiveness. Our study
emphasizes the importance of communicational as-
pects such as approachability, empathy, support and
active listening. Contrary to Percival et al. partici-
pants in our qualitative study mentioned a clear
need for intensified contact. A higher frequency
and longer duration of consultations were sug-
gested. Not only communication with the patients,
but also between health care professionals should
be improved.
Needs of patients were explored in-depth and partici-
pants provided suggestions on how to improve guidance.
This knowledge is needed to improve guidance in clin-
ical practice.
The sample may not have been a cross-section of
SGA users. Patients who have a strong opinion about
their received guidance will possibly be more inclined
to contribute to focus group discussions. Therefore, it
is uncertain if the results are generalizable. Our pa-
tient selection consisted of patients who succeeded to
initiate treatment and adhered to treatment for at
least six weeks, with more than half of the partici-
pants on SGA treatment for more than six months.
Some participants used SGA’s for over ten years and
might not have remembered guidance during start of
treatment precisely, which could have led to recall
bias.
A next step would be to discuss suggested solu-
tions with health care professionals to assess their
views and to discuss the possibility for implementa-
tion. Future studies could be aimed at determin-
ation of its impact on patients’ treatment efficacy,
quality of life, treatment satisfaction and healthcare
costs.
Conclusions
Participants were in need of better guidance. Al-
though improvement of guidance in clinical practice
is comprehensive and complex, our study provides
recommendations from patients themselves on
needs and how to improve guidance, which are
highlighted in Table 2. Content, communication
and organization of guidance are pivotal for achiev-
ing optimal guidance. Participants additionally re-
ported potential (already experienced) barriers. The
recommendations from patients can aid health care
professionals to improve guidance in clinical
practice.
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Table 2 Patients’ needs, suggestions and cited barriers for improvement on guidance by health care professionals




Before the decision to fill a prescription
Information needed on:
- cause of symptoms
- treatment options
Shared decision making, incorporating patients’
needs
Patients might not be capable of making a
choice in case of severe symptoms
Incorporate time before initiation of an
antidepressant to consider the decision to
initiate treatment
The physician should choose the most
accurate medication
Provide a protocol for physicians to help select
the most accurate medication by using
questions on disease symptoms of patients and
to assess side effects and laboratory values
During the decision to initiate SGA therapy
Information needed on:
- rationale behind drug choice
- mechanism of action
- harm/benefit balance
- expected effects and side effects (also
during discontinuation)
- potential worsening of symptoms during
start of treatment
Mention needed information explicitly Patients might be reluctant to start therapy
when knowing potential side effects
Provide patient leaflets (also within psychiatric
institutions)
During the decision to adhere to or to discontinue treatment




- the patients’ wellbeing
- if the patient considers discontinuation
- medication use and experiences
- the patients’ social network
- suicidal thoughts
Evaluate treatment with the patient Limited time of a consultation
Provide a guideline for patients to evaluate
efficacy, dosage and side effects of the
antidepressant
If necessary, discuss the possibility to switch
treatment
Evaluation form or questionnaire to assess side
effects together with the patient
During the decision to discontinue treatment
Guidance during long term antidepressant
use is needed to assess if the dosage needs
to be adjusted, and to decide to continue
or discontinue treatment
Assess whether it is necessary to continue
treatment and provide information on the
expected treatment duration
Patients may change their dosage or discontinue
treatment without informing their health care
professional
Guide the patient during long-term use and if
the decision is to discontinue therapy, give
practical tips on how to do so.
Communication aspects
Communication between the health care professional and the patient
- take patients seriously
- be empathic
- provide direct contact
- be accurate
- respect the patient
- attitude of thinking along
- respect the autonomy of the patient
Carefully listen to the patients’ story Some participants thought psychiatrists were
not emphatic enough
Provide a combination of a psychiatrist with a
psychologist
Provide the ability to choose for a male of
female health care professional
Some patients may not be assertive enough to
request this
Mutual trust between the physician and
patient
Keep a sound registration of information
gathered in previous appointments
Some participants did not trust their physician
if they could not recall conversations,
medication dosages, gave opposing advice,
made mistakes in prescriptions or were chaotic
Equality between health care professionals
and patients
Show equality in posture and respect for the
patient
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Appendix Abbreviations
SGA: Second generation antidepressant
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Table 2 Patients’ needs, suggestions and cited barriers for improvement on guidance by health care professionals (Continued)
Patient needs Suggestions for improvement of guidance by
health care professionals
Barriers
Communication between health care professionals
Improvement of communication between
health care specialists
Information should be transferred on the
patients’ medical history and conflicting ideas
between health care professionals should be
solved to prevent confusion of the patient
For the patient it should be clear which
health care professional to consult
Assign a responsible health care specialist to
keep track of a patient, assess if the treatment is
still adequate and to assess wellbeing of the patient
It was not clear who the responsible health
care specialist should be
Possibility to be admitted to a psychiatric hospital
Organization of guidance
Periodical visits during initiation and (long-
term) treatment. It should be known when
the next appointment is
Physician should be responsible for initiative of
contact and discuss the preferred frequency
with the patient
Patient might be not assertive enough to
request a consultation
Longer duration of a consultation
Involve social network during medication
initiation
If wanted: involve social network during
medication initiation.
Physicians and pharmacists should advise not
to initiate the antidepressant without a relative
or caregiver monitoring them
Not all participants wanted to involve other
persons in treatment or did not have a social
network
Possibility to contact a psychiatrist when
needed
Daily conversation hour, even by email or by
phone, by the physician or pharmacist (also
within psychiatric institutions)
Physician might not have time due to high
workload
Provide a stand-by 24-h helpline for patients in
need
Inability of helpline operator to have insight
into the patients’ medical file
Provide an anonymous chat forum leaded by a
psychiatrist and not visible for everyone
Reading other patients experiences can make
patients anxious and others could write nonsense
More privacy in pharmacies Provide more privacy in pharmacies
Checks during repeat prescriptions Provide an alert for repeat prescriptions If a stock is inadequate, the patient might
receive medication too late
In case a prescription is not filled, call a patient
to ask for the reason
Health care professional should have
enough knowledge on treatment
Only psychiatrists should prescribe
antidepressants
Some patients have a better relation with their
general practitioner
Some participants did not wat to see their
psychiatrists too frequently
Knowledge of general practitioners and
pharmacists should be improved
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